A comprehensive view of european medicines agency (ema). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

CHMP adopts positive opinion recommending approval of Bristol Myers Squibb’s Opdivo nivolumab in combination with Cisplatin and Gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma
Published: April 26, 2024 by Bristol-Myers Squibb Co.
Phase 3 study of Roche's OCREVUS subcutaneous injection shows near-complete suppression of multiple sclerosis relapse activity and lesions; approval anticipated from FDA and EMA in 2024
Published: April 17, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Bristol-Myers Squibb receives EMA's positive opinion on anemia therapy, bolsters collaborative health initiatives, and continues technological advancement in disease treatment
Published: February 24, 2024 by Industry Intelligence Inc.
FDA grants priority review to Regeneron's BLA for linvoseltamab as a treatment for multiple myeloma, decision date is set for August 22, 2024; European medicines agency accepted the drug for review earlier this month
Published: February 21, 2024 by Regeneron Pharmaceuticals Inc.
Bristol Myers announces acceptance of US and EU regulatory filings for neoadjuvant opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant opdivo in resectable non-small cell lung cancer
Published: February 07, 2024 by Bristol-Myers Squibb Co.

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count